Summary:
- The article discusses the new RSV (respiratory syncytial virus) vaccine called nirsevimab, which is being recommended for infants and young children.
- It raises concerns about the lack of long-term safety data for this vaccine, as it has only been tested in clinical trials for a short period of time.
- The article also highlights the potential risks associated with the vaccine, including the possibility of antibody-dependent enhancement, and calls for more thorough safety studies before widespread use.